Name of the drug:Suzetrigine
Introduction:In 2025 FDA approved this drug and it is commercially being used as under the name of JOURNAVX
It is a non opioid analgesic
Mechanism of action
Suzetrigine stops the signalling of pain to reach to brain by selectively blocking NaV1.8 sodium channel which is primarily responsible for transmitting of pain
After that pain signalling get reduced.
Indications
This drug is basically used in the case of moderate and severe pain in adults
Can be used as post operative pain killer too.
Adverse effects
- Rash
- Increased level of creatine phosphokinase
- Muscle spasms
- Pruritis
Contraindications
- It should not be used along strong CYP3A inhibitors
- Grapefruit should be avoided
- Only be used for short period of time
Dosage
100mg orally as an initial dose can be administered followed with 50mg every 12 hours
Key takeaway
Instead of targeting opioid receptors,Suzetrigine is new approach for pain management that targets sodium gated channel.
Could Non opioid analgesic will become a good alternative for opioid analgesic?
Share your views!